Treatment with tamoxifen leads to an increased risk for thromboembolic events, including stroke, pulmonary embolism, and deep venous thrombosis, as well as endometrial cancer because of its partial estrogenic activity.3 Heart failure is associated with trastuzumab and anthracycline (eg, doxorubicin) treatment. Acute leukemia and myelodysplastic syndrome is associated with alkylating agents (cyclophosphamide) and type II topoisomerase inhibitors (including anthracyclines). Radiation of the left chest wall also increases the risk of coronary artery disease. Hand and foot erythema with or without pain is a frequent acute adverse effect of capecitabine (5-fluorouracil) therapy.
- Deep venous thrombosis.
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet 1998;351:145167.
Click here to return to the questions
Seminars in Medical Practice
Hospital Physician Board Review Manuals
Copyright © 2009, Turner White Communications
Updated 1/04/08 kkj